NASDAQ:SCPS

Scopus BioPharma Competitors

$7.82
+0.03 (+0.39 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.53
Now: $7.82
$8.00
50-Day Range
$7.57
MA: $8.89
$10.52
52-Week Range
$5.34
Now: $7.82
$47.86
Volume17,719 shs
Average Volume154,649 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Scopus BioPharma (NASDAQ:SCPS) Vs. ABCL, SANA, ABCM, SEER, NUVB, and IBRX

Should you be buying SCPS stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Scopus BioPharma, including AbCellera Biologics (ABCL), Sana Biotechnology (SANA), Abcam (ABCM), Seer (SEER), Nuvation Bio (NUVB), and ImmunityBio (IBRX).

AbCellera Biologics (NASDAQ:ABCL) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares AbCellera Biologics and Scopus BioPharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbCellera BiologicsN/AN/AN/AN/AN/A
Scopus BioPharmaN/AN/AN/AN/AN/A

Profitability

This table compares AbCellera Biologics and Scopus BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbCellera BiologicsN/AN/AN/A
Scopus BioPharmaN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for AbCellera Biologics and Scopus BioPharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbCellera Biologics00503.00
Scopus BioPharma01002.00

AbCellera Biologics presently has a consensus price target of $52.80, indicating a potential upside of 86.90%. Scopus BioPharma has a consensus price target of $20.00, indicating a potential upside of 155.75%. Given Scopus BioPharma's higher possible upside, analysts clearly believe Scopus BioPharma is more favorable than AbCellera Biologics.

Summary

AbCellera Biologics beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sana Biotechnology and Scopus BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sana BiotechnologyN/AN/AN/A
Scopus BioPharmaN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Sana Biotechnology and Scopus BioPharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sana Biotechnology02202.50
Scopus BioPharma01002.00

Sana Biotechnology presently has a consensus price target of $40.00, indicating a potential upside of 59.74%. Scopus BioPharma has a consensus price target of $20.00, indicating a potential upside of 155.75%. Given Scopus BioPharma's higher possible upside, analysts clearly believe Scopus BioPharma is more favorable than Sana Biotechnology.

Earnings & Valuation

This table compares Sana Biotechnology and Scopus BioPharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sana BiotechnologyN/AN/AN/AN/AN/A
Scopus BioPharmaN/AN/AN/AN/AN/A

Summary

Sana Biotechnology beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.

Scopus BioPharma (NASDAQ:SCPS) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Valuation & Earnings

This table compares Scopus BioPharma and Abcam's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/AN/AN/AN/A
AbcamN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Scopus BioPharma and Abcam, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Scopus BioPharma01002.00
Abcam04302.43

Scopus BioPharma currently has a consensus target price of $20.00, indicating a potential upside of 155.75%. Abcam has a consensus target price of $22.00, indicating a potential upside of 12.47%. Given Scopus BioPharma's higher possible upside, research analysts clearly believe Scopus BioPharma is more favorable than Abcam.

Profitability

This table compares Scopus BioPharma and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Scopus BioPharmaN/AN/AN/A
AbcamN/AN/AN/A

Summary

Abcam beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Profitability

This table compares Seer and Scopus BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Scopus BioPharmaN/AN/AN/A

Earnings & Valuation

This table compares Seer and Scopus BioPharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Scopus BioPharmaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Seer and Scopus BioPharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Scopus BioPharma01002.00

Seer currently has a consensus target price of $68.00, indicating a potential upside of 26.25%. Scopus BioPharma has a consensus target price of $20.00, indicating a potential upside of 155.75%. Given Scopus BioPharma's higher probable upside, analysts plainly believe Scopus BioPharma is more favorable than Seer.

Summary

Seer beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Profitability

This table compares Nuvation Bio and Scopus BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
Scopus BioPharmaN/AN/AN/A

Valuation & Earnings

This table compares Nuvation Bio and Scopus BioPharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
Scopus BioPharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Nuvation Bio and Scopus BioPharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
Scopus BioPharma01002.00

Nuvation Bio currently has a consensus price target of $17.40, indicating a potential upside of 74.52%. Scopus BioPharma has a consensus price target of $20.00, indicating a potential upside of 155.75%. Given Scopus BioPharma's higher probable upside, analysts clearly believe Scopus BioPharma is more favorable than Nuvation Bio.

Summary

Nuvation Bio beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Profitability

This table compares ImmunityBio and Scopus BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Scopus BioPharmaN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for ImmunityBio and Scopus BioPharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Scopus BioPharma01002.00

ImmunityBio presently has a consensus price target of $25.00, suggesting a potential upside of 38.35%. Scopus BioPharma has a consensus price target of $20.00, suggesting a potential upside of 155.75%. Given Scopus BioPharma's higher probable upside, analysts clearly believe Scopus BioPharma is more favorable than ImmunityBio.

Valuation and Earnings

This table compares ImmunityBio and Scopus BioPharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Scopus BioPharmaN/AN/AN/AN/AN/A

Summary

ImmunityBio beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks.


Scopus BioPharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AbCellera Biologics logo
ABCL
AbCellera Biologics
1.5$28.25+0.0%$7.61 billionN/A0.00Increase in Short Interest
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$25.04+3.4%$4.70 billionN/A0.00News Coverage
Abcam logo
ABCM
Abcam
1.5$19.56+0.6%$4.43 billionN/A0.00News Coverage
SEER
Seer
1.2$53.86+5.7%$3.28 billionN/A0.00Increase in Short Interest
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$9.97+0.4%$2.17 billionN/A0.00Analyst Report
Insider Buying
News Coverage
IBRX
ImmunityBio
1.7$18.07+7.2%$1.98 billionN/A0.00Gap Down
Immunocore logo
IMCR
Immunocore
1.3$39.50+16.5%$1.70 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.7$46.04+0.1%$1.55 billionN/A0.00News Coverage
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$35.47+9.0%$1.54 billionN/A0.00
EWTX
Cricut
0.3$28.15+1.0%$1.34 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.29+11.0%$1.34 billionN/A0.00Analyst Report
News Coverage
KNTE
Kinnate Biopharma
1.7$30.72+7.6%$1.34 billionN/A0.00Increase in Short Interest
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.99+11.4%$1.33 billionN/A0.00Earnings Announcement
Analyst Report
Insider Selling
Increase in Short Interest
News Coverage
Vor Biopharma logo
VOR
Vor Biopharma
1.9$33.72+13.6%$1.25 billionN/A0.00News Coverage
FDMT
4D Molecular Therapeutics
1.1$37.68+5.1%$1.01 billionN/A0.00Increase in Short Interest
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$17.45+2.9%$974.01 millionN/A0.00Analyst Report
News Coverage
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$29.59+2.5%$942.15 millionN/A0.00Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.96+8.3%$870.42 millionN/A0.00Analyst Report
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.94+7.1%$848.39 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$23.99+4.0%$842.03 millionN/A0.00Analyst Report
Increase in Short Interest
PHAR
Pharming Group
0.0$13.00+1.9%$829.48 millionN/A0.00Decrease in Short Interest
News Coverage
FNCH
Finch Therapeutics Group
2.0$16.66+2.0%$785.44 millionN/A0.00Analyst Report
News Coverage
SGTX
Sigilon Therapeutics
1.4$19.88+6.2%$626.08 millionN/A0.00Increase in Short Interest
News Coverage
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$21.65+17.8%$543.96 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$23.89+12.3%$543.69 millionN/A0.00News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
1.4$13.60+2.9%$540.43 millionN/A0.00News Coverage
Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.54+2.0%$496.21 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Landos Biopharma logo
LABP
Landos Biopharma
1.8$11.26+5.8%$451.73 millionN/A0.00News Coverage
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.75+2.8%$451.17 millionN/A0.00
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.13+5.6%$446.09 millionN/A0.00Gap Up
PRTG
Portage Biotech
0.0$28.17+3.8%$340.38 millionN/A0.00Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.61+2.5%$306.86 millionN/A-2.98
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.87+3.6%$291.75 millionN/A-2.72
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.83+3.9%$269.69 millionN/A0.00
IPA
ImmunoPrecise Antibodies
0.0$10.94+7.3%$209.16 millionN/A0.00Increase in Short Interest
LBPH
Longboard Pharmaceuticals
1.9$12.15+2.4%$205.54 millionN/A0.00Analyst Report
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$22.90+5.4%$167.63 millionN/A0.00
GANX
Gain Therapeutics
1.7$14.02+5.8%$158.90 millionN/A0.00Analyst Report
VINC
Vincerx Pharma
1.0$19.05+0.6%$156.31 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$7.33+11.2%$140.73 millionN/A0.00News Coverage
LGVN
Longeveron
0.3$7.49+2.3%$140.12 millionN/A0.00News Coverage
UPC
Universe Pharmaceuticals
0.0$3.92+4.3%$85.26 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$14.46+6.3%$56.51 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.31+2.3%$54.58 millionN/A0.00Gap Down
VIRI
Virios Therapeutics
1.3$5.90+0.8%$49.15 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.29+2.1%$38.75 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.87+5.1%$33.17 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3N/AN/A$23.39 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$35.01+12.4%$16.25 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.84+4.9%$15.69 millionN/A0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.